Darrin Uecker - 09 Jun 2022 Form 4 Insider Report for Pulse Biosciences, Inc. (PLSE)

Role: Director
Signature: /s/ Kenneth B. Stratton, as Attorney-in-Fact
Issuer symbol: PLSE
Transactions as of: 09 Jun 2022
Net transactions value: $0
Form type: 4
Filing time: 10 Jun 2022, 18:57:53 UTC
Next filing: 02 May 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PLSE	Common Stock	Exercise of in-the-money or at-the-money derivative security		+7,365	+5.7%		137,376	09 Jun 2022	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PLSE	Warrant (right to buy)	Purchase		+7,365			7,365	09 Jun 2022	Common Stock	7,365	$2.05	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Reporting Person acquired the shares of common stock and the warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering (the "Rights Offering"), as disclosed in the Registration Statement on Form S-3, as amended, and the Prospectus Supplement and certain Current Reports on Form 8-K filed by the Issuer with the SEC.
F2	Pursuant to the terms of the Rights Offering, the Reporting Person purchased units at a price of $2.05 per unit, with each unit consisting of one share of common stock and a warrant to purchase one share of common stock at an exercise price of $2.05.